301207 华兰疫苗
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.6533.1223.34814.62612.514
总资产报酬率 ROA (%)0.5462.5462.64911.4128.960
投入资产回报率 ROIC (%)0.6523.0343.18113.86811.346

边际利润分析
销售毛利率 (%)70.92077.80181.15388.08988.089
营业利润率 (%)151.25415.78219.05141.90432.462
息税前利润/营业总收入 (%)150.05015.46918.39741.56431.989
净利润/营业总收入 (%)139.55315.21218.22235.67728.463

收益指标分析
经营活动净收益/利润总额(%)-53.65396.38277.61999.640117.066
价值变动净收益/利润总额(%)46.41947.67846.78410.94212.290
营业外收支净额/利润总额(%)-0.070-1.060-0.145-0.315-0.535

偿债能力分析
流动比率 (X)4.1453.9243.3993.1012.728
速动比率 (X)3.9013.7643.2562.9982.619
资产负债率 (%)16.04816.65620.07321.66622.316
带息债务/全部投入资本 (%)-0.314-0.1904.4434.1244.853
股东权益/带息债务 (%)-31,796.911-52,467.2202,134.3452,307.4211,945.534
股东权益/负债合计 (%)523.123500.388398.192361.563348.118
利息保障倍数 (X)-136.721-105.200-29.372-199.512-106.640

营运能力分析
应收账款周转天数 (天)4,260.601416.940547.106282.792318.997
存货周转天数 (天)2,553.437261.658323.749213.562227.277